Alzheimer abeta peptide binding polypeptide

a technology of alzheimer's disease and binding polypeptide, which is applied in the field of alzheimer's disease abeta peptide binding polypeptide, can solve the problems of no treatment that significantly alters the course of the disease or efficiently stops its development, and achieves the effects of improving the folding of fusion proteins, increasing expression, and increasing stability
US20180057551A1Inactive Publication Date: 2018-03-01AFFIBODY TECH AB
5 Cites 1 Cited by

Patent Information

Authority / Receiving Office
US · United States
Current Assignee / Owner
AFFIBODY TECH AB
Publication Date
2018-03-01
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid β (Aβ) peptides (in the following referred to as Aβ), comprising the amino acid sequence EX2X3YX5X6NLX9AX11QLCAX16IX18X19X20 ED. The present disclosure also relates to the use of such Aβ peptide binding polypeptides as therapeutic, prognostic and / or diagnostic agents.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTION

[0001] The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid β (Aβ) peptide (in the following referred to as Aβ). The present disclosure also relates to the use of such Aβ peptide binding polypeptides as therapeutic, prognostic and / or diagnostic agents.BACKGROUND

[0002] Many different diseases, such as Alzheimer's disease, type II diabetes, primary and secondary systemic amyloidosis, and familial amyloid polyneuropathy 1, have been recognized as belonging to the growing family of amyloid diseases. All amyloid diseases have in common the presence of extracellular protein aggregates that may or may not be fibrillar.

[0003] Alzheimer's disease (AD) is the leading cause of dementia worldwide, with approximately 35 million people affected. Current treatments for Alzheimer's disease provide only modest symptomatic relief, and there is a great need for therapies that slow the course of the disease and prevent or delay th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More